B. Braun Medical lands $33M loan to build sterile injection plant in Indonesia

B. Braun Medical
B. Braun Medical gets loan to build injectables plant in Indonesia.

German pharma B. Braun Medical has landed a $33 million loan from the International Finance Corporation (IFC), a member of the World Bank Group, to help fund the construction of a sterile injectables plant in Indonesia.

The overall cost of the facility has been pegged at about $100 million and would be, when completed, one of the company’s biggest manufacturing plants.

The factory is expected to have the capacity to produce 150 million units of intravenous liquids as well as injectable medical products after both phases of construction are completed in about four years, a company spokesman said. The plant will employ around 800 people when finished.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

“Apart from fulfilling the needs of the Indonesian market, more than 50 percent of the production will be exported to the Asia-Pacific region, Japan and Australia, and to Europe,” said Stephan Soyka, a managing director of B. Braun’s Indonesian operations.

The facility will be designed to meet manufacturing standards of the Therapeutic Goods Administration, Australia’s regulator for medical drugs and devices, and the FDA.

In May, B. Braun agreed to settle a Department of Justice action and pay almost $8 million in penalties, forfeiture and restitution to resolve its criminal liability related to the sale of contaminated prefilled saline flush syringes that dated back to 2007.

- here’s the IFC release
- check out a Jakarta Globe story

Related Articles:
B. Braun settles with the DOJ over contaminated syringes

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.